In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 |
| 10-K | 10-K | 10-K |
Revenues: |
Non-US | 6.9 | 20.0 | 5.8 |
Other | 62.5 | 108.1 | 45.8 |
Revenues | 69.4 | 128.1 | 51.6 |
Revenue growth [+] | -45.8% | 148.0% | |
Non-US | -65.5% | 244.8% | |
Cost of goods sold | 0.5 | 3.0 | 3.9 |
Gross profit | 68.9 | 125.0 | 47.8 |
Gross margin | 99.3% | 97.6% | 92.5% |
Selling, general and administrative [+] | 35.8 | 25.6 | 7.7 |
Sales and marketing | 4.8 | 5.1 | 1.5 |
General and administrative [+] | 25.6 | 16.8 | 3.8 |
General and administrative expenses | 11.3 | 4.4 | 0.5 |
Professional fees | 14.3 | 12.5 | 3.4 |
Other selling, general and administrative | 5.5 | 3.7 | 2.4 |
Research and development | 11.5 | 8.2 | 4.6 |
Other operating expenses | 145.5 | 94.7 | 37.3 |
EBITDA [+] | -123.9 | -3.5 | -1.9 |
EBITDA growth | 3422.9% | 83.0% | |
EBITDA margin | -178.6% | -2.7% | -3.7% |
Depreciation | 2.0 | 0.6 | 0.2 |
EBITA | -125.9 | -4.1 | -2.1 |
EBITA margin | -181.5% | -3.2% | -4.1% |
Amortization of intangibles | 4.0 | 4.8 | 2.2 |
EBIT [+] | -129.9 | -8.9 | -4.3 |
EBIT growth | 1358.7% | 105.8% | |
EBIT margin | -187.3% | -7.0% | -8.4% |
Non-recurring items | 5.1 | 0.9 | 3.3 |
Interest expense, net [+] | -2.7 | 2.3 | 2.4 |
Interest expense | | 2.3 | 2.4 |
Interest income | 2.7 | | |
Other income (expense), net [+] | 20.8 | -6.0 | -0.5 |
Change in fair value of warrants | 19.8 | -6.1 | -0.3 |
Other | 0.9 | 0.0 | -0.2 |
Pre-tax income | -111.6 | -18.1 | -10.5 |
Income taxes | 0.3 | 0.4 | -0.8 |
Tax rate | | | 7.6% |
Minority interest | 0.0 | | |
Net income | -111.9 | -18.5 | -9.7 |
Net margin | -161.2% | -14.4% | -18.8% |
|
Basic EPS [+] | ($0.78) | ($0.34) | ($0.26) |
Growth | 128.2% | 30.9% | |
Diluted EPS [+] | ($0.77) | ($0.34) | ($0.26) |
Growth | 126.4% | 30.9% | |
|
Shares outstanding (basic) [+] | 143.8 | 54.3 | 37.3 |
Growth | 164.9% | 45.5% | |
Shares outstanding (diluted) [+] | 145.0 | 54.3 | 37.3 |
Growth | 167.1% | 45.5% | |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |